Colorado BioScience Association
Colorado BioScience Association

Colorado BioScience Association Names Jack Wheeler Chairperson, Announces 2007 Sponsors and Appoints Eight New Board Members

Jack Wheeler, CEO of MicroPhage, Inc., Longmont, is the new chairperson of the board of directors for the Colorado BioScience Association (CBSA). He was appointed at the association’s 2007 annual meeting April 24th. Wheeler assumes chairperson responsibilities from Ed Wood, ArcScan, Inc. In other action, eight new board members were appointed to three-year terms.

Denver, CO, May 18, 2007 --( Jack Wheeler, CEO of MicroPhage, Inc. (, Longmont, was named chairperson of the board of directors for the Colorado BioScience Association (CBSA) at its 2007 annual all-member meeting held at the GlobeImmune/Replidyne dual headquarters facility in Louisville, Colo., April 24. The announcement is made by Denise Brown, CBSA executive director, who says Wheeler assumes chairperson responsibilities from Ed Wood, ArcScan, Inc.

Prior to introducing Wheeler to the CBSA membership, Wood announced the following 2007 association sponsors: Platinum – Amgen, Colorado Science + Technology Park at Fitzsimons, Hogan & Hartson, Colorado State University, Cooley Godward Kronish L.L.P., and University of Colorado Technology Transfer. Silver – Faegre & Benson L.L.P, Pfizer, Fitzsimons Redevelopment Authority, Ernst & Young, ABD Insurance and Financial Services, Metro Denver Economic Development Corporation, Gambro, and Snell & Wilmer, L.L.P. Bronze – Johnson and Johnson, Commerce Bank, Holland & Hart, Fairfield and Woods, P.C., PhRMA, OSI Pharmaceuticals, CBR International and vcfo.

New vice chairperson of the CBSA board is Rick Jory, CEO of Sandhill Scientific (, headquartered in Highlands Ranch. In other action, eight new board members were appointed, expanding the CBSA board to 40 members.

The CBSA board is comprised of members from traditional biotechnology companies, traditional medical device companies, research organizations, service providers and emerging companies. New CBSA board members receiving three-year appointments include: Derek Cole, Allos Therapeutics; Doug Henston, Solix Biofuels; Chris Lepore, Johnson & Johnson; Dan Mitchell, Sequel Venture Partners; Harry Ross, Aweida Venture Partners; Michael Salem, National Jewish Medical and Research Center; Greg Tucker, OSI Pharmaceuticals; and M. Roy Wilson, University of Colorado.

Bios follow of the newly appointed board members:

* Derek Cole, Vice President Investor Relations for Allos Therapeutics ( has been involved in the capital markets and strategic planning for over 16 years with 11 years of dedicated investor relations experience focused on supporting the development of small- and mid-cap companies. He has managed or contributed to a broad spectrum of financing transactions, raising approximately $800 million, as well as supporting four M&A transactions. Prior to Allos, Cole headed the investor relations and corporate communications function at Myogen, Inc., from its days as a private company, through its Initial Public Offering and continuing until its recent $2.5 billion acquisiton by a larger biotech company. He is an active member of both the National Investor Relations Institute (NIRI) and the Colorado BioScience Association.

* Doug Henston is the Chief Executive Officer of Solix Biofuels ( Solix is an early stage Colorado company that is developing scalable technology to enable the commercial production of biofuels from algae. Prior to joining the company, Henston was a strategic consultant in carbon mitigation strategies and renewable energy with Domani Sustainability Consulting. There he helped corporations understand their carbon footprints and the strategic value of greenhouse gas mitigation through renewable energy technology and participation in the carbon credit markets, both domestically and internationally. Prior to moving to Colorado, Henston was a vice president in the fixed income group at Goldman Sachs. He served in the United States Navy as a Naval Aviator from 1984 to 1992, deploying twice to the Mediterranean Ocean. Doug holds a B.S. in Molecular Biophysics and Biochemistry from Yale University and an MBA from the Harvard Business School.

* Chris Lepore is the Director of State Government Affairs for Johnson & Johnson ( and chair of the Pharmaceutical Researchers and Manufacturers of America - Colorado Task Force. Lepore joined Johnson & Johnson in 2004. He brings with him a strong government affairs background having 14 years of legislative and regulatory experience. Before joining Johnson & Johnson he was Manager of State Government Affairs for Schering-Plough Corporation, where he was responsible for the corporation's lobbying efforts in Arizona, Colorado, New Mexico, Utah, and Wyoming. In addition to Lepore’s industry experience, he has been a contract lobbyist in Colorado and Wyoming, representing the business interests of Hoffman LaRoche, the Colorado Association of Commerce and Industry, the Business Council for Health Care, and served on the PAC of the National Federation of Independent Business. Lepore is a graduate of the University of Northern Colorado where he received a Bachelor of Arts Degree in Communications. Johnson & Johnson, through its operating companies is the world's most comprehensive and broadly based manufacturer of health care products. Johnson & Johnson is the second largest biotech company in the world and Johnson & Johnson's medical device companies develop, market and sell more medical devices than any other company in the world.

* Dan J. Mitchell, Partner, Sequel Venture Partners ( co-founded Capital Health Venture Partners in 1985, a health care focused venture capital firm based in Chicago and Denver. As a Partner with Capital Health, Mitchell focused primarily on early-stage investments across healthcare. Mitchell’s investment career began in 1981 at First National Bank of Chicago. In 1983 he joined the Bank’s Institutional Venture Capital Fund where he invested in numerous industry segments including computer hardware and software, networking products, semiconductor equipment and specialty chemicals. Mitchell has served on the board of directors of numerous public and private companies and is currently a director of CardioOptics, Inc.; GlobeImmune, Inc.; Myogen, Inc. (NASDAQ: MYOG); and Replidyne, Inc. Mitchell majored in finance and accounting at the University of Illinois and received his Bachelor of Science degree in 1979. He received an M.B.A. from the Graduate School of Business at the University of California, Berkley in 1981.

* Harry Ross, Aweida Capital Management (, received his Doctor of Medicine degree from Oregon Health Science University in 1991. He then went on to receive post graduate training in Surgery and Emergency Medicine at Hennepin County Medical Center with subsequent National Board Certification in Emergency Medicine. Dr. Ross retired from clinical practice in 1998 to join Aweida Capital where he is a Managing Partner specializing in the Life Sciences. Aweida Capital Management is a 15 year old Evergreen Fund responsible for the management of its own private assets. The fund participates from early seed to late mezzanine rounds with preferred lifetime investments within a company of $5-10 million. Areas of interest are Life Sciences, Software, Data Storage, and Alternative Energy. The fund currently has $100 million under management.

* Michael Salem, M.D., FACS, began his tenure as President and CEO of National Jewish Medical and Research Center ( in January 2006, bringing to the position a combination of academic and business experience in the healthcare field. A native of Washington, D.C., Dr. Salem received his undergraduate degree at Washington University in St. Louis, and then returned to his hometown for his medical degree from George Washington University School of Medicine and Health Sciences. He completed his surgical residency training at Boston University Hospital and George Washington University Hospital. He also completed research and clinical fellowships in Critical Care Medicine at Massachusetts General Hospital in Boston and Johns Hopkins Hospital in Baltimore. After the completion of his medical training, Dr. Salem practiced and taught general surgery and critical care at George Washington University Hospital, where he later served as Vice Chairman of the Department of Surgery. Later in his career, Dr. Salem served as the Executive Vice President of a healthcare company that develops and commercializes biotechnology and medical technology products from academic medical centers. He led the research and development operations of that company, building research facilities and programs and navigating the regulatory process to bring discoveries to the marketplace. In his first year at National Jewish, Dr. Salem led a comprehensive, broad-based strategic planning process that included faculty, staff, Board members, the Council of National Trustees and healthcare leaders from around the world. The ten year vision and plan, approved by the Board of Directors in January 2007, is a compelling set of ideas and solutions that will result in the integration of research and clinical efforts at the point of the patient. The plan will allow National Jewish to continue to innovate and lead as a medical center, remain preeminent in its areas of focus, maintain its collegial culture and grow substantially over time.

* Greg Tucker has 18 years experience in the pharmaceutical industry. He has worked in a variety of commercial capacities in larger pharma (Roche), mid-size pharma (Gilead), small start-up firms (Synergen, NeXstar) as well as the medical device industry (COBE BCT). His experience includes leadership assignments in business development, strategic planning, new product planning, marketing, sales, managed care, commercial operations, project management and strategic brand management. While at OSI (, Tucker has held a variety of positions in the Oncology Commercial Group. He served as Project Head for the Team that licensed the oncology rights to Novantrone from Serono. As Senior Director, Marketing and Sales, he was responsible for building and leading the Marketing, Sales, Training and Operations groups at OSI. Subsequently, he was promoted to Vice President, US Commercial Operations expanding his executive role in the Oncology Business Unit at OSI. Currently, he holds the position of Vice President, Strategic Management and Operations where he leads company activities for strategic brand management, project management, portfolio management and business decision and analysis. Tucker holds a BS in Pharmacy from the University of Arkansas and a MS in Health Administration (specialty in Pharmaceutical Marketing) from the University of Mississippi.

* Dr. M. Roy Wilson began serving as chancellor of the University of Colorado at Denver and Health Sciences Center ( in July, 2006. He is an elected member of the Institutes of Medicine of the National Academy of Sciences, the American Ophthalmological Society, and the Glaucoma Society of the International Congress of Ophthalmology. Dr. Wilson’s major scientific contributions have been in bridging the fields of epidemiology and ophthalmology. He actively participates on numerous national boards and committees, with particular focus on ophthalmology and on the health of underserved populations. Among these are the Academy of Medicine, Engineering and Science of Texas, EyeCare America (the Glaucoma Project of the American Academy of Ophthalmology), and the Association of International Glaucoma Society’s Committee on Global Research and Screening, for which he is the co-chair. Additionally, Dr. Wilson was an initial Advisory Council member of the National Center on Minority Health and Health Disparities of the National Institutes of Health and served four years as chair of its Strategic Plan subcommittee. Dr. Wilson received his medical degree from Harvard Medical School and his Master of Science in epidemiology at the UCLA School of Public Health. He performed both his ophthalmology residency and glaucoma fellowship at the Massachusetts Eye and Ear Infirmary, Harvard Medical School. Dr. Wilson was named president of the Texas Tech University Health Sciences Center in 2003. In 1998, he was appointed dean of the School of Medicine at Creighton University, and then served as both dean and vice president for Health Sciences from 1999-2003. Prior to that time, he was professor of ophthalmology both at the Jules Stein Eye Institute of UCLA and Charles R. Drew University of Medicine & Science. Dr. Wilson has delivered more than 200 invited lectures, many of these internationally, and has published more than 200 articles, book chapters and abstracts.

CBSA recently released its fourth annual issue of Colorado Bioscience Magazine at the BIO International Conference in Boston. A link to a pdf of the new magazine is found at:

About Colorado BioScience Association

Colorado BioScience Association is a not-for-profit corporation providing services and support for Colorado’s growing biosciences industry. Colorado is carrying out an aggressive plan to grow the state’s bioscience industry into one of the country’s premier bioscience clusters. CBSA currently enjoys the support of more than 340 member organizations representing both bioscience companies and companies providing key services to the bioscience industry and research institutions in Colorado. The association’s main office is located in the Advance Colorado Center, 1625 Broadway, Suite 950, in Denver, plus satellite offices are maintained in the Fitzsimons Bioscience Park and the Fort Collins Technology Incubator. A new chapter was recently announced in Colorado Springs. You can learn more about CBSA at the website


Denise Brown, Executive Director, Colorado BioScience Association, – 303.592.4073 or 303.915.9762, E-mail:

Maggie Chamberlin Holben, APR, Absolutely Public Relations, – 303.984.9801 or 303.669.3558, E-mail:

Colorado BioScience Association
Maggie Holben